Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
BeiGene, Ltd. BGNE
$237.85
-$6.57 (-2.76%)
На 18:00, 12 мая 2023
-13.81%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
25380706760.00000000
-
week52high
280.62
-
week52low
118.18
-
Revenue
1415921000
-
P/E TTM
-13
-
Beta
0.78754300
-
EPS
-20.14000000
-
Last Dividend
0.00000000
-
Next Earnings Date
08 авг 2018 г. в 00:00
Описание компании
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; XGEVA to treat giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; Pamiparib for the treatment of various solid tumors; and Pobevcy to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC). The company's clinical stage drug candidates comprise Zanubrutinib, a BTK inhibitor to treat lymphomas; Tislelizumab, an anti-PD-1 antibody to treat solid and hematological cancers; Lifirafenib and BGB-3245 to treat melanoma, NSCLC, and endometrial cancer; and Sitravatinib, a multi-kinase inhibitor to treat NSCLC, melanoma, and other solid tumors. Its clinical stage drug candidates also include BGB-A333, a PD-L1 inhibitor to treat various solid tumors; Ociperlimab, a TIGIT inhibitor to treat various solid tumors; BGB-11417, a small molecule Bcl-2 inhibitor to treat mature B-cell malignancies; BGB-A445, an OX40 agonist antibody to treat solid tumors; Zanidatamab, a bispecific HER2 inhibitor to treat breast and gastric cancer; BGB-A425, a T-cell immunoglobulin and mucin-domain containing-3 inhibitor to treat various solid tumors; and BGB-15025, a small molecule inhibitor of HPK1. The company has strategic collaborations with Shoreline Biosciences, Inc., Amgen Inc., Novartis AG, and Bristol Myers Squibb company. BeiGene, Ltd. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Overweight | Overweight | 15 июл 2022 г. |
| Morgan Stanley | Overweight | Overweight | 09 мая 2022 г. |
| Morgan Stanley | Overweight | Overweight | 12 апр 2022 г. |
| SVB Leerink | Market Perform | Outperform | 17 мар 2022 г. |
| SVB Leerink | Outperform | Outperform | 28 февр 2022 г. |
| SVB Leerink | Outperform | Market Perform | 13 окт 2022 г. |
| Morgan Stanley | Overweight | Overweight | 13 окт 2022 г. |
| Guggenheim | Buy | Neutral | 13 окт 2022 г. |
| SVB Leerink | Outperform | Outperform | 10 ноя 2022 г. |
| SVB Leerink | Outperform | Outperform | 12 дек 2022 г. |
| SVB Leerink | Outperform | Outperform | 20 янв 2023 г. |
| Guggenheim | Buy | Buy | 20 янв 2023 г. |
| Morgan Stanley | Overweight | Overweight | 24 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Wang Xiaodong | D | 0 | 901 | 12 янв 2023 г. |
| Wang Xiaodong | D | 901 | 4099 | 12 янв 2023 г. |
| Wang Xiaodong | D | 0 | 100 | 11 янв 2023 г. |
| Wang Xiaodong | D | 100 | 950 | 11 янв 2023 г. |
| Wang Xiaodong | D | 1050 | 1250 | 11 янв 2023 г. |
| Wang Xiaodong | D | 2300 | 200 | 11 янв 2023 г. |
| OYLER JOHN | D | 0 | 193 | 10 янв 2023 г. |
| OYLER JOHN | D | 193 | 1947 | 10 янв 2023 г. |
| OYLER JOHN | D | 2140 | 1336 | 10 янв 2023 г. |
| OYLER JOHN | D | 3476 | 2442 | 10 янв 2023 г. |
Новостная лента
3 Top Biotech Stocks Defying the Bear Market
The Motley Fool
25 апр 2023 г. в 08:45
TG Therapeutics' MS drug Briumvi has had strong early sales. Viking Therapeutics reports solid clinical results from its obesity drug VK2735.
7 Biotech Stocks That Could Cure Your Portfolio Woes
InvestorPlace
19 апр 2023 г. в 19:22
Fundamentally, the driving catalyst for biotech stocks to buy centers on the possibility of supporting paradigm-shifting medical breakthroughs. For example, a report published by the JAMA Network indicates that experts project the global economic cost of cancers from 2020 to 2050 will be $25.2 trillion (in constant 2017 dollar terms).
The FDA Is Resuming Drug Lab Inspections in China. These Biotechs Could Benefit.
Barrons
14 апр 2023 г. в 14:45
China's pandemic-era travel restrictions paused approvals on some new drugs. The end of Zero Covid means the pipeline will reopen.
BeiGene, Ltd. (BGNE) Surges 12.5%: Is This an Indication of Further Gains?
Zacks Investment Research
10 апр 2023 г. в 04:35
BeiGene, Ltd. (BGNE) saw its shares surge in the last session with trading volume being higher than average.
Why BeiGene Stock Jumped Thursday
The Motley Fool
06 апр 2023 г. в 17:24
BeiGene's shares are up more than 8% this year. The company has more than 60 clinical programs.